Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding

Yasushi Yamasaki, Ryuta Takenaka, Keisuke Hori, Koji Takemoto, Seiji Kawano, Yoshiro Kawahara, Shigeatsu Fujiki, Hiroyuki Okada

Research output: Contribution to journalArticle

Abstract

The usefulness of endoscopy in marginal ulcer bleeding has rarely been studied, and the optimal method for preventing rebleeding is unclear. Here we assessed the efficacy of endoscopy in marginal ulcer bleeding and examined the efficacy of proton pump inhibitors (PPIs) in the prevention of rebleeding. A total of 28 patients with marginal ulcer bleeding (21 men, 7 women; median age 58.5 years) were treated by endoscopy. We analyzed the clinical characteristics, results of endoscopic therapy, characteristics of rebleeding patients, and relation between the use of PPIs and the duration of rebleeding. Sixteen patients had active bleeding. Initial hemostasis was achieved in all patients. There were no procedure-related adverse events. Rebleeding occurred in one patient within the first month and in 7 patients thereafter. There was a significant difference in the rebleeding rate between the patients who received a PPI and those who did not. In a multivariate analysis, the non-use of PPIs was a risk factor for rebleeding (hazard ratio, 6.22). Therapeutic endoscopy is effective in achieving hemostasis from marginal ulcer bleeding. PPIs may prevent rebleeding from marginal ulcers.

Original languageEnglish
Pages (from-to)469-475
Number of pages7
JournalActa Medica Okayama
Volume70
Issue number6
Publication statusPublished - 2016

Fingerprint

Endoscopic Hemostasis
Proton Pump Inhibitors
Peptic Ulcer
Endoscopy
Hemorrhage
Hemostasis
Hazards
Multivariate Analysis
Therapeutics

Keywords

  • Endoscopic hemostasis
  • Marginal ulcer
  • Proton-pump inhibitor
  • Upper gastrointestinal bleeding

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding. / Yamasaki, Yasushi; Takenaka, Ryuta; Hori, Keisuke; Takemoto, Koji; Kawano, Seiji; Kawahara, Yoshiro; Fujiki, Shigeatsu; Okada, Hiroyuki.

In: Acta Medica Okayama, Vol. 70, No. 6, 2016, p. 469-475.

Research output: Contribution to journalArticle

Yamasaki, Y, Takenaka, R, Hori, K, Takemoto, K, Kawano, S, Kawahara, Y, Fujiki, S & Okada, H 2016, 'Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding', Acta Medica Okayama, vol. 70, no. 6, pp. 469-475.
Yamasaki, Yasushi ; Takenaka, Ryuta ; Hori, Keisuke ; Takemoto, Koji ; Kawano, Seiji ; Kawahara, Yoshiro ; Fujiki, Shigeatsu ; Okada, Hiroyuki. / Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding. In: Acta Medica Okayama. 2016 ; Vol. 70, No. 6. pp. 469-475.
@article{a0d5bd6d30e0420a934a3ec84bcb08db,
title = "Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding",
abstract = "The usefulness of endoscopy in marginal ulcer bleeding has rarely been studied, and the optimal method for preventing rebleeding is unclear. Here we assessed the efficacy of endoscopy in marginal ulcer bleeding and examined the efficacy of proton pump inhibitors (PPIs) in the prevention of rebleeding. A total of 28 patients with marginal ulcer bleeding (21 men, 7 women; median age 58.5 years) were treated by endoscopy. We analyzed the clinical characteristics, results of endoscopic therapy, characteristics of rebleeding patients, and relation between the use of PPIs and the duration of rebleeding. Sixteen patients had active bleeding. Initial hemostasis was achieved in all patients. There were no procedure-related adverse events. Rebleeding occurred in one patient within the first month and in 7 patients thereafter. There was a significant difference in the rebleeding rate between the patients who received a PPI and those who did not. In a multivariate analysis, the non-use of PPIs was a risk factor for rebleeding (hazard ratio, 6.22). Therapeutic endoscopy is effective in achieving hemostasis from marginal ulcer bleeding. PPIs may prevent rebleeding from marginal ulcers.",
keywords = "Endoscopic hemostasis, Marginal ulcer, Proton-pump inhibitor, Upper gastrointestinal bleeding",
author = "Yasushi Yamasaki and Ryuta Takenaka and Keisuke Hori and Koji Takemoto and Seiji Kawano and Yoshiro Kawahara and Shigeatsu Fujiki and Hiroyuki Okada",
year = "2016",
language = "English",
volume = "70",
pages = "469--475",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "6",

}

TY - JOUR

T1 - Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding

AU - Yamasaki, Yasushi

AU - Takenaka, Ryuta

AU - Hori, Keisuke

AU - Takemoto, Koji

AU - Kawano, Seiji

AU - Kawahara, Yoshiro

AU - Fujiki, Shigeatsu

AU - Okada, Hiroyuki

PY - 2016

Y1 - 2016

N2 - The usefulness of endoscopy in marginal ulcer bleeding has rarely been studied, and the optimal method for preventing rebleeding is unclear. Here we assessed the efficacy of endoscopy in marginal ulcer bleeding and examined the efficacy of proton pump inhibitors (PPIs) in the prevention of rebleeding. A total of 28 patients with marginal ulcer bleeding (21 men, 7 women; median age 58.5 years) were treated by endoscopy. We analyzed the clinical characteristics, results of endoscopic therapy, characteristics of rebleeding patients, and relation between the use of PPIs and the duration of rebleeding. Sixteen patients had active bleeding. Initial hemostasis was achieved in all patients. There were no procedure-related adverse events. Rebleeding occurred in one patient within the first month and in 7 patients thereafter. There was a significant difference in the rebleeding rate between the patients who received a PPI and those who did not. In a multivariate analysis, the non-use of PPIs was a risk factor for rebleeding (hazard ratio, 6.22). Therapeutic endoscopy is effective in achieving hemostasis from marginal ulcer bleeding. PPIs may prevent rebleeding from marginal ulcers.

AB - The usefulness of endoscopy in marginal ulcer bleeding has rarely been studied, and the optimal method for preventing rebleeding is unclear. Here we assessed the efficacy of endoscopy in marginal ulcer bleeding and examined the efficacy of proton pump inhibitors (PPIs) in the prevention of rebleeding. A total of 28 patients with marginal ulcer bleeding (21 men, 7 women; median age 58.5 years) were treated by endoscopy. We analyzed the clinical characteristics, results of endoscopic therapy, characteristics of rebleeding patients, and relation between the use of PPIs and the duration of rebleeding. Sixteen patients had active bleeding. Initial hemostasis was achieved in all patients. There were no procedure-related adverse events. Rebleeding occurred in one patient within the first month and in 7 patients thereafter. There was a significant difference in the rebleeding rate between the patients who received a PPI and those who did not. In a multivariate analysis, the non-use of PPIs was a risk factor for rebleeding (hazard ratio, 6.22). Therapeutic endoscopy is effective in achieving hemostasis from marginal ulcer bleeding. PPIs may prevent rebleeding from marginal ulcers.

KW - Endoscopic hemostasis

KW - Marginal ulcer

KW - Proton-pump inhibitor

KW - Upper gastrointestinal bleeding

UR - http://www.scopus.com/inward/record.url?scp=85013103812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013103812&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 469

EP - 475

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 6

ER -